Thomas Strungmann

Thomas Strüngmann founded generic drug maker Hexal AG in 1986. In 2005, he and his brother Andreas sold Hexal for $6.7B. They earned $8B on their stake in BioNTech SE, the German company developing the Pfizer vaccine. They own approximately 50% of the company as well as significant ownership in 4SC and Immatics.